Background {#Sec1}
==========

Heimler syndrome (HS) was first reported in 1991 by A. Heimler as an inherited syndrome characterized by sensorineural hearing loss (SNHL), enamel hypoplasia, and nail abnormalities \[[@CR1]\]. Biallelic mutations in the peroxisomal biogenesis factor 1 gene (*PEX1*; MIM\*602136), peroxisomal biogenesis factor 6 gene (*PEX6*; MIM\*601498), and peroxisomal biogenesis factor 26 gene (*PEX26*; MIM\* 608666) are responsible for HS \[[@CR2]--[@CR4]\]. The proteins they encode function together to control peroxisomal matrix protein import, and mutations of these genes are implicated in peroxisome biogenesis disorders (MIM phenotypic series PS214100). These are characterized by a deficiency of essential peroxisomal functions or even a complete loss of functional peroxisomes, resulting in a wide range of phenotypes that vary in severity \[[@CR5], [@CR6]\]. Patients with the most serious phenotype present at birth only live a few weeks or months (Zellweger syndrome) \[[@CR7]\], while some disorders generally present later in childhood, primarily with leukodystrophy, SNHL, retinal dystrophy, and developmental and cognitive delay. Others may have multiple organ dysfunction and psychomotor impairments including craniofacial dysmorphism, neurological abnormalities, sensory defects, and liver, kidney, and bone abnormalities \[[@CR5]\]. Therefore, patients with HS represent the mildest phenotypic subgroup \[[@CR8], [@CR9]\].

Our current knowledge of HS is very limited, with only 29 reported patients worldwide; 26 of these have genetic sequence information \[[@CR1]--[@CR4], [@CR9]--[@CR14]\]. HS is also a systemic disease with a variety of other co-existing congenital abnormalities, and diagnostic criteria have not been proposed \[[@CR2], [@CR15]\]. The HS clinical phenotype varies, but includes acquired SNHL, amelogenesis imperfecta of the teeth, and retinal dystrophy, partially clinically overlapping with Usher syndrome that is characterized by congenital deafness, retinitis pigmentosa (RP), presence or absence of vestibular dysfunction, but no dental anomalies \[[@CR4]\]. Although the number of reported cases is small, this does not reflect a low incidence of disease; rather many cases are misdiagnosed or may not even be diagnosed at all, because of the clinical evaluation alone is especially difficult and often not definitive \[[@CR4]\]. Thus, an evidence-based, early, accurate, and fast diagnostic approach is in great need. Fortunately, next-generation sequencing (NGS) methods have been shown to be a powerful tool for the diagnosis of genetic or presumed genetic disorders \[[@CR16], [@CR17]\]. In this study, we accurately diagnosed two HS patients using NGS and presented their comprehensive ophthalmic examinations. We further reviewed the varied phenotypes and genotypes of all previously reported cases, and uncovered novel genotype--phenotype correlations.

Methods {#Sec2}
=======

Subjects and ethics statement {#Sec3}
-----------------------------

The current study was performed in accordance with the Code of Ethics of the World Medical Association (Declaration of Helsinki) for medical research involving human subjects, and was approved by the Ethics Committee of the Eye & ENT Hospital of Fudan University. Two HS patients and their relatives were recruited after obtaining informed consent.

Clinical evaluation and sample collection {#Sec4}
-----------------------------------------

Both patients underwent a full ophthalmic examination, including best corrected Snellen visual acuity testing (BCVA), color vision (Ishihara color plate), slit lamp biomicroscopy, tonometry, dilated fundus examination, ultrasound biomicroscopy (UBM), A/B-ultrasound (MD-300 L; MEDA Co., Ltd., Tianjin, China), wide-field fundus imaging (Optos PLC, Dunfermline, United Kingdom), spectral domain optical coherence tomography (SD-OCT, Spectralis HRA + OCT, Heidelberg, Engineering Inc., Heidelberg, Germany), full-field electroretinography (ERG, according to the standards of the International Society for Clinical Electrophysiology of Vision; available at [www.iscev.org](http://www.iscev.org)), multifocal ERG (mfERG, LKC Utas E3000 LKC Technologies Inc., USA), and visual field (Humphrey Visual Field Analyzer, Carl Zeiss Inc., CA, USA). Family and medical history including subjective degree of vision loss, age of onset and other related clinical manifestations were recorded. Blood samples of all the patients and their family members were collected from the peripheral blood and stored at 4°Cbefore further analysis.

Genetic analyses and confirmation of suspected pathogenic variants {#Sec5}
------------------------------------------------------------------

DNA samples were extracted from whole blood using the FlexiGene DNA Kit (Qiagen, Venlo, The Netherlands) according to the manufacturer's protocol. All participants in this study were subjected to analysis using this panel-based NGS. The capture panel contains exon-capture and untranslated regions (UTRs) of 762 genes that are involved in common inherited eye diseases (BGI-Shenzhen, Additional file [3](#MOESM3){ref-type="media"}: Table S1). Acquisition of probe sequences: obtain the exon sequence and its flank ±30 bp of 762 genes from hg38. Each reference sequence begins at one end of a reference sequence and selects the reference sequence of the predetermined length to obtain the probe sequence so that the last total probe can cover the reference sequence at least once, and the probe length of the panel is 90 nt, the total target area obtained is 2.3 M. On average, the mean coverage depth was more than 400X and the coverage of target region was around 99.9% by using BGISEQ-500. Subsequent points for sample quality control have also been added to the probe design process. After sequencing, data analysis was performed as reported previously \[[@CR18], [@CR19]\]. Previously reported variants were determined using ClinVar (<https://www.ncbi.nlm.nih.gov/clinvar/>), the Human Gene Mutation Database (HGMD Professional 2018.4, <http://www.hgmd.cf.ac.uk/ac/index.php>), and locus-specific databases. Variants were classified as pathogenic and likely pathogenic according to the American College of Medical Genetics (ACMG) and genomics guidelines for the more recent cases. Before confirmation by Sanger sequencing, the candidate variants were reviewed by clinical geneticists and ophthalmologists. Segregation analysis was performed within family members.

Results {#Sec6}
=======

Genetic analyses of the two patients {#Sec7}
------------------------------------

Two previously reported mutations, c.2966 T \> C (p.Ile989Thr, maternally inherited) and c.2097_2098insT (p.Phe699Phefs\*43, paternally inherited) \[[@CR2], [@CR9]\], were found in patient 1. A known missense mutation, c.2966 T \> C (p.Ile989Thr, maternally inherited) \[[@CR2], [@CR9]\], and a novel likely pathogenic mutation, c.895_896insTATA (p.Asn299Ilefs\*2, paternally inherited), were found in patient 2. Pedigrees and identified mutations of the two families are shown in Fig. [1](#Fig1){ref-type="fig"}. We found no additional pathogenic or likely pathogenic variants known to be associated with inherited eye diseases in either patient. Fig. 1Pedigrees (**a**) and identified mutations (**a**). **a** Circles represent females, and squares represent males. Filled symbols represent affected patients, and empty symbols represent unaffected family members. **b** Sequencing results of the mutations in the *PEX*1 gene. Arrows indicate the position of the mutated nucleotide

Clinical features of the two patients {#Sec8}
-------------------------------------

Patient 1 is a 9-year-old boy, and patient 2 is an 8-year-old girl. Clinical characteristics of the two patients are summarized in Table [1](#Tab1){ref-type="table"}. Their family history was unremarkable. Both patients had SNHL since birth and amelogenesis imperfecta on their secondary teeth. Nails, development, and intelligence were normal (Additional file [1](#MOESM1){ref-type="media"}: Figure S1 and Additional file [2](#MOESM2){ref-type="media"}: Figure S2). They suffered from a progressive decrease in visual acuity and nyctalopia since birth. BCVA values of patient 1 and 2 were 0.8/0.6 and 0.4/0.5, respectively, and intraocular pressures were within the normal range. There were no abnormalities in anterior segments. Fundus examinations revealed midperipheral and peripheral retinal pigmentation abnormalities in both patients, consistent with RP (Figs. [2](#Fig2){ref-type="fig"} and [3](#Fig3){ref-type="fig"}). SD-OCT showed marked loss and disruption of the ellipsoid zone, photoreceptor outer segment, and retinal pigment epithelium (RPE). Cystoid macular edema (CME) was seen in both patients, although cystoid spaces were larger and more frequent in patient 2. Interestingly, both patients were previously diagnosed with Usher syndrome as well as attention deficit hyperactivity disorder (ADHD), their axial lengths (20.69 mm/20.49 mm vs 20.17 mm/20.30 mm, respectively) were shorter than their peers, and they suffered from hyperopia (+ 3.25/+ 3.75 DS vs + 3.75/+ 1.65 DS, respectively). Table 1Summary of mutations, ophthalmologic findings, and other features of the two patientsCase 1Case 2Ethnicity/genderChinese/maleChinese/femaleAge of eye examination (years)98Mutation*PEX*1 c.2966 T \> C; p.Ile989Thr*PEX*1 c.2097_2098insT; p.Phe699Phefs\*43*PEX*1 c.895_896insTATA p.Asn299Ilefs\*2 *PEX*1 c.2966 T \> C p.Ile989ThrFamily historyUnremarkableUnremarkableOphthalmic findings -IOP (mmhg)10/109/10 -BCVA0.8/0.60.4/0.5 - Cycloplegic refractionR: + 3.25/+ 2.75X85L: + 3.75/+ 3.00X85R: + 3.75/− 0.5X67L: + 1.65/− 0.37X88 - Color amblyopiaColor amblyopiaN - CorneaNN -Corneal curvatureR: 41.11/45.36 DL: 41.01/44.53 DR: 45.55/46.30 DL: 45.98/46.49 D -Central corneal thickness563 um/563 umNA - Anterior chamber depth2. 65 mm/2.54 mm1.99 mm/1.99 mm - IrisNN - Axial lengths20.69 mm/20.49 mm20.17 mm/20.30 mm - LensNN -UBMNN - Retinal vesselsNN -RetinaRetinal atrophy in the mid and far periphery combined with significant bone spicule-like pigmentationRetinal atrophy in the mid and far periphery combined with significant bone spicule-like pigmentation - Optic nerveThe inferionasal rim of the optic disc is blurred (R and L)The inferionasal rim of the optic disc is blurred (R and L) -B scanLight to moderate turbidity in the front and middle sections of the vitreous, posterior vitreous detachmentLight turbidity in the front and middle sections of the vitreous, posterior vitreous detachment -RNFL thicknessNN -ffERGProfoundly attenuated rod ERGs, subnormal and delayed cone ERGs.Undetectable rod ERG, subnormal bright flash ERG, subnormal and delayed cone ERG. -mfERGAmplitudes in posterior-pole of both eyes were significantly reduced, more seriously in the right eyeAmplitudes in posterior-pole of both eyes were significantly reduced, more seriously in the right eye -VEPReduced of P100 amplitude.Prolongation of latency and lowness of amplitude. - Humphrey visual fieldPeripheral visual field loss, with small central lossPeripheral visual field loss, except for the superior nasal quadrant - Goldman visual fieldNAPeripheral visual field constriction -SD-OCTCentrally preserved ISe band with small retinal cysts of the inner nuclear layerMultiple large intraretinal cysts - Orbital MRINN - Sensorineural hearing loss++ -TeethAmelogenesis imperfectaAmelogenesis imperfecta - Nail abnormalitiesNN - IntellectNN - ElectroencephalographyThe frequency of theta rhythm is slightly increasedNA - DevelopmentNN - PsychomotorNNAbbreviations. *IOP* intraocular pressure, *BCVA* best corrected visual acuity, *R* right, *L* left, *SD-OCT* spectral domain optical coherence tomography, *UBM* ultrasound biomicroscopy, *RNFL* retinal nerve fiber layer, *MRI* magnetic resonance, *ffERG* full-field ERG, *mfERG* multifocal ERG, *VEP* visual evoked potential, *ISe* inner segment ellipsoid, *N* normal, *NA* not assessed, + positive finding Fig. 2Ocular features of patient 1. **a** Ultra wide-field pseudocolor images showing retinal atrophy in the mid and far periphery combined with significant bone spicule-like pigmentation and mottling in both eyes. **b** SD-OCT shows small macular cysts in the inner nuclear layer, a thickened retina, and an atrophic photoreceptor layer with preservation of the ellipsoid zone (EZ) and the external limiting membrane (ELM). **c** Visual field shows peripheral visual field loss, with small central loss. **d** mfERG shows that amplitudes in the posterior-pole of both eyes were significantly reduced, more seriously in the right eye Fig. 3Ocular features of patient 2. **a** Ultra wide-field pseudocolor images showing retinal atrophy in the mid and far periphery combined with significant bone spicule-like pigmentation, mottling in both eyes. **b** SD-OCT shows bilateral cystoid macular edema, which mainly involved the outer nuclear layer (ONL). The foveal and peripheral macular ellipsoid zone (EZ) was disrupted and almost absent. **c** Visual field shows peripheral visual field loss except for the superior nasal quadrant. **d** mfERG shows undetectable rod ERG, subnormal bright flash ERG, and subnormal and delayed cone ERG

Follow-up visits were scheduled 2 months and 2 years after the first visit of patient 2. At the 2-month visit, CME was aggravated and the central foveal thickness (CFT) increased from 510 to 603 μm in the right eye and from 599 to 666 μm in the left eye; as a result, the BCVA decreased from 0.6/0.7 to 0.4/0.5. At the third visit 2 years later, the CFT of both eyes had decreased spontaneously; however, through anatomic improvement, there was no notable visual gain (Fig. [4](#Fig4){ref-type="fig"}). The thickness of all other retinal layers showed no major change throughout the 2 year-follow-up (Additional file [4](#MOESM4){ref-type="media"}: Table S2). Fig. 4Follow-up of central foveal thickness in patient 2

Genotype--phenotype correlations {#Sec9}
--------------------------------

Clinical and genetic characteristics of the previously reported HS cases were analyzed and are listed in Table [2](#Tab2){ref-type="table"}. To date, 29 HS patients have been reported worldwide, which gives a total of 31 including the two patients in this study (male = 10, female = 21). Among the 29 reported HS patients, most derive from the UK (*n* = 10) and the USA (*n* = 8), while only one is of Chinese origin. Twelve patients from seven families harbor *PEX6* mutations, 10 patients from eight families carry *PEX1* mutations, and two patients from two families have *PEX26* mutations. No variants were identified in the currently known *PEX* genes in four patients from two families by exome sequencing \[[@CR9]\], while genetic testing was undertaken in three patients from three families. Together with our study, 15 missense mutations (71.4%, *PEX1* = 4/8, *PEX6* = 8/10, *PEX26* = 3/3), four frameshift mutations (19.0%, *PEX*1 = 2/8, *PEX6* = 2/10), one nonsense mutation (4.8%, *PEX1* = 1/8), and one splicing mutation (4.8%, *PEX1* = 1/8) have been reported to be associated with HS. Only 50 missense mutations (29.4%, *PEX1* = 21/85, *PEX6* = 27/76, *PEX26* = 2/9) were reported to be associated with Zellweger syndrome, which has a severe early-lethal clinical presentation (Additional file [5](#MOESM5){ref-type="media"}: Table S3), while the remaining 70.6% of variants are truncating stop or frameshift defects. Table 2Phenotype and genotype of individuals with HS reportedGenePatients IDOriginSexAgeVariantsOcular featuresSNHLNailToothOthersReference*PEX*11F1--1USAM31c.2114 T \> G c.2097dupRP, MD.+Beau's lines, leukonychiaAmelogenesis imperfectaN\[[@CR1]\]2F1--2USAF29c.2114 T \> G c.2097dupRP, MD.+Beau's lines, leukonychiaAmelogenesis imperfectaN\[[@CR1]\]9F6--1MoroccoF16c.3750G \> A c.3750G \> AN+NAmelogenesis imperfectaN\[[@CR9]\]10F6--2MoroccoM12c.3750G \> A c.3750G \> AN+NAmelogenesis imperfectaN\[[@CR9]\]11F7--1IrelandF19c.1742G \> C c.1239 + 1G \> TNA+NAmelogenesis imperfectaN\[[@CR9]\]12F8--1UKF24c.1742G \> C c.2097dupRP+NAmelogenesis imperfectaN\[[@CR9]\]18F11--1MoroccanF13c.3140 T \> C c.3140 T \> CRP, CME.+NAmelogenesis imperfectaN\[[@CR3]\]27F17--1ChinaM45c.1792delA c.2966 T \> CRetinal dystrophy+Beau's linesAmelogenesis imperfectaMild learning disability, paranoid schizophrenia, dry split skin on hands; ichthyosis over limbs\[[@CR2]\]30F20--1ChinaM9c.2966 T \> C c.2097_2098insTRP, CME.+NAmelogenesis imperfectaHyperactivity, abnormal EEG,θincreases slightly in wake backgroundThis study31F21--1ChinaF8c.2966 T \> C c.895_896insTATARP, CME.+NAmelogenesis imperfectaHyperactivityThis study*PEX*66F4--1UKF21c.1802G \> A c.1841delTRP+Beau's lines, leukonychiaAmelogenesis imperfectaN\[[@CR12]\]7F4--2UKF21c.1802G \> A c.1841delTRP+Beau's lines, leukonychiaAmelogenesis imperfectaN\[[@CR12]\]19F12--1USAMNAc.654C \> G c.1802G \> ARetinal dystrophyNANAAmelogenesis imperfectaNA\[[@CR2]\]20F12--2USAFNAc.654C \> G c.1802G \> ARetinal dystrophyNANAAmelogenesis imperfectaNA\[[@CR2]\]21F12--3USAMNAc.654C \> G c.1802G \> ARetinal dystrophyNANAAmelogenesis imperfectaNA\[[@CR2]\]22F13--1USAM12c.275 T \> G c.1802G \> ARetinal dystrophy+Beau's linesAmelogenesis imperfectaHyperpigmentation on left arm and shoulder\[[@CR2]\]23F14--1USAF7c.296G \> T c.1802G \> ARetinal dystrophy+NAmelogenesis imperfectaN\[[@CR2]\]24F15--1UKF11c.1314_1321delGGAGGCCTc.2714G \> TRetinal dystrophy+NAAmelogenesis imperfectaNA\[[@CR2]\]25F16--1IsraelF35c.1715C \> T c.1715C \> TRetinal dystrophy+NAmelogenesis imperfectaMild learning disability, Light facial lesions\[[@CR2]\]26F16--2IsraelF22c.1715C \> T c.1715C \> TRetinal dystrophy+NAmelogenesis imperfectaMild learning disability, light facial lesions\[[@CR2]\]13F9--1UKF21c.1930C \> T c.821C \> TRP+Beau's lines, onychoschiziaAmelogenesis imperfectaN\[[@CR9]\]14F9--2UKF16c.1930C \> T c.821C \> TRP+Beau's lines, onychoschiziaAmelogenesis imperfectaN\[[@CR9]\]*PEX*2628F18--1GermanyF4c.3G \> A c.292C \> TRP+NAAmelogenesis imperfectaNA\[[@CR4]\]29F19--1GermanyM14c.127G \> Cc.292C \> TRP+NAAmelogenesis imperfectaNA\[[@CR4]\]--15F10--1UKF21--N+NAmelogenesis imperfectaN\[[@CR9]\]16F10--2UKM20--N+NAmelogenesis imperfectaN\[[@CR9]\]17F10--3UKM16--N+NAmelogenesis imperfectaN\[[@CR9]\]3F2--1UKF12--NA+Beau's lines,Amelogenesis imperfectaN\[[@CR14]\]NA4F3--1German and Irish ancestryF15NANA+Beau's lines,Amelogenesis imperfectaN\[[@CR13]\]5F3--2German and Irish ancestryF8NANA+Beau's lines,Amelogenesis imperfectaN\[[@CR13]\]8F5--1USAF29NARP, CME.+Beau's lines, leukonychiaAmelogenesis imperfectaN\[[@CR11]\]Abbreviations. *F* female, *M* male, *N* normal, *NA* not assessed, + positive finding, *SNHL* sensorineural hearing loss, *RP* retinitis pigmentosa, − no variants were identified in currently known *PEX* genes, *MD* macular dystrophy, *CME* cystoid macular edema

The genotype of every HS patient include at least one missense variant, except for two patients from one family with a homozygous exon 23 nonsense variant, c.3750G \> A (p.Trp1250\*). This variant is only 19 bases from the last exon--exon boundary of *PEX1*, and it is likely that the resultant transcript escapes nonsense-mediated decay with little effect on protein function, resulting in a mild phenotype. We found a genotype--phenotype relationship in HS patients with retinal dystrophy that at least one mutation in *PEX1* or *PEX6* gene affected the nucleotide sequence of the AAA-ATPase region in every patient, which is typically involved in binding of substrates or cofactors and is vital for the *PEX* function^19--21^. These results suggesting that AAA-ATPase region may is a hypermutable region in patients with retinal dystrophy. The locations of these variants are shown in Fig. [5](#Fig5){ref-type="fig"}. Fig. 5Location of HS-associated variants in *PEX1*, *PEX6* and *PEX26.* Black: missense mutation. Blue: splicing mutation. Red: frameshift mutation. Green: nonsense mutation

All 31 patients were diagnosed with enamel defects of the secondary teeth and SNHL. Twenty patients had RP with or without macular cystoid dystrophy, while no fundus examination was performed on the other four patients so it is unknown if they had RP. Funduscopy of five patients from two families was normal. Twelve patients have nail abnormalities, suggesting that this is not an essential phenotype so should not be a clinical diagnostic indicator for HS \[[@CR12]\]. HS was shown to be a rare disease with high phenotypic heterogeneity, with no significant difference between *PEX1-*, *PEX6-*, and *PEX26*-associated phenotypes.

Discussion {#Sec10}
==========

Phenotypic information about individual patients is often insufficiently detailed or inaccessible, thus obstructing the diagnosis of rare systemic diseases or those with overlapping phenotypes. Gene panel sequencing achieves high diagnostic rates in the context of a specific suspected disease or group of diseases, and genetic results can provide support for clinical diagnosis, modify future disease risk, and inform the customization of a variety of therapies \[[@CR16], [@CR17]\].

So far, our clinical knowledge and understanding of HS are very limited and a diagnosis can easily be overlooked or misdiagnosed. In this work, two patients previously diagnosed with Usher syndrome achieved an accurate diagnosis of HS based on NGS. Additionally, a novel pathogenic mutation and two unreported ocular phenotypes were recognized, and four novel genotype--phenotype correlations of HS were uncovered. This provides a deeper understanding of the clinical manifestations and pathogenesis of HS, which is vital for accurate clinical practice, genetic counseling, and pathogenesis studies.

No details of HS ophthalmic manifestations caused by *PEX1* mutations have been reported so far. In this work, we present comprehensive ophthalmic examinations of two HS patients induced by *PEX1* mutations. As well as the previously reported phenotypic features of RP with CME, these patients also showed short axial lengths and hyperopia suggesting that *PEX1* mutation-associated ocular involvement can be developmental (short axial length) and degenerative (RP). Both patients also had ADHD which may be a novel phenotype of HS. After comprehensively analyzing the varied phenotypes of all reported HS cases in the literature, we propose that HS is a systemic disorder with high phenotypic variability; however, all cases demonstrate SNHL (severe to profound) and enamel hypoplasia of secondary dentition. Most patients show infantile-onset retinal dystrophy, and nails are normal or abnormal. They may also suffer from other systemic abnormalities such as learning disabilities or ADHD. Considering the wide clinical heterogeneity, rapid and definitive diagnosis of HS is challenging, and it is especially difficult to establish clinical diagnostic criteria. NGS can help resolve these challenges, and we suggest that it should become the "gold standard" for diagnosing HS.

Through a comprehensive analysis of the reported mutant genes we found that mutations in *PEX1* and *PEX6* are the main cause of HS. A small number of cases are also caused by mutations in *PEX26*, and it is likely that other HS-causing genes remain to be discovered. *PEX1* and *PEX6* are members of the AAA protein family that are involved in binding ATP to form a heterohexameric ATPase which is associated with various cellular activities that fuel essential protein transport across peroxisomal membranes \[[@CR20], [@CR21]\]. They also play a key role in matrix protein import from heterohexamers and ternary complexes with *PEX26* \[[@CR22]\]. Mutant *PEX6* and *PEX1* proteins result in abnormal peroxisomal function, leading to the accumulation of very long chain fatty acids in photoreceptors, RPE, and pigment-laden macrophages \[[@CR10], [@CR23]\].

Genotype--phenotype analysis in this study revealed that HS is caused by genotypes including at least one missense variant, while Zellweger syndrome was caused by more deleterious genotypes, such as truncating stop or frameshift defects. Furthermore, at least one mutation in one patient affects the AAA-ATPase region (*PEX1* and *PEX6*) or *PEX6* binding site (*PEX26*) when HS patients have retinal dystrophy. Together, these results we speculate that hypomorphic mutations in *PEX* result in a partially functional protein \[[@CR24], [@CR25]\], mutations in AAA-ATPases play a role in retinal dystrophy, and AAA-ATPase region is a hypermutable region in patients with a retinal dystrophy. No significant difference was found among *PEX1*-, *PEX6*-, and *PEX26*-associated phenotypes, perhaps because these genes closely interact in vivo so any mutation in a given gene affects the function of the entire complex \[[@CR26], [@CR27]\]. It is also conceivable that a single genetic locus cannot explain the full phenotypic spectrum, and we propose that additional genetic and possibly nongenetic modifiers cause the various phenotypes.

One limitation of this study is that the genotype--phenotype correlations were based on only 31 HS patients. Therefore, these correlations should be confirmed in more HS patients in future studies. Additionally, only one HS patient was followed up over a 2-year period, which may not accurately reflect the progress of the disease. Longer follow-up in more HS patients is required to better understand the ocular prognosis of this disease.

Conclusions {#Sec11}
===========

To summarize, we report two HS families diagnosed by NGS and present the first comprehensive report of the HS ophthalmic phenotype. We identified a novel pathogenic mutation and two unreported ocular phenotypes, which expands the known mutation and clinical spectra of HS. Furthermore, we propose that HS is a systemic disorder with high phenotypic heterogeneity, and show the importance of NGS in the diagnosis of HS. Three novel genotype--phenotype correlations of HS were also uncovered, which is useful for accurate clinical practice, genetic counseling, and pathogenesis studies. These data should be validated and expanded in additional studies.

Supplementary information
=========================

 {#Sec12}

**Additional file 1: Figure S1.** Clinical characteristics of patient 1. A and B: the hearing test demonstrated the presence of sensorineural hearing loss. C and D: The clinical appearance of teeth and orthopantograms show severe amelogenesis imperfecta. E: Fingernails and toenails are normal, and no Beau's lines or leukonychia were observed. **Additional file 2: Figure S2.** Clinical characteristics of patient 2. A and B: The hearing test shows that both ears suffered from SNHL since birth. C and D: The clinical appearance of teeth and orthopantograms show severe amelogenesis imperfecta. E: Fingernails and toenails are normal, and no Beau's lines or leukonychia were observed. **Additional file 3: Table S1.** Gene list of capture panel (762 genes). **Additional file 4: Table S2**. Follow-up of intraretinal layer thickness in patient 2. **Additional file 5: Table S3.** Reported pathogenic variants in *PEX1*, *PEX6*, and *PEX26* in the Human Gene Mutation Database associated with Zellweger syndrome.

ACMG

:   American College of Medical Genetics

ADHD

:   Attention deficit hyperactivity disorder

ATP

:   Adenosine triphosphate

BCVA

:   Best corrected visual acuity testing

CFT

:   Central foveal thickness

CME

:   Cystoid macular edema

ERG

:   Full-field electroretinography

HGMD

:   Human Gene Mutation Database

HS

:   Heimler syndrome

IOP

:   Intraocular pressure

NGS

:   Next-generation sequencing

OMIM

:   Online Mendelian Inheritance in Man

PBDs

:   Peroxisome biogenesis disorders

RP

:   Retinitis pigmentosa

RPE

:   Retinal pigment epithelium

SD-OCT

:   Spectral domain optical coherence tomography

SNHL

:   Sensorineural hearing loss

UBM

:   Ultrasound biomicroscopy

UTRs

:   Untranslated regions

**Publisher's Note**

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Feng-Juan Gao and Fang-Yuan Hu contributed equally to this work.

Supplementary information
=========================

**Supplementary information** accompanies this paper at 10.1186/s13023-019-1243-x.

We would like to thank all patients and their family members for their collaboration. We are grateful to the technical staff at Eye and ENT Hospital of Fudan University for their assistance and BGI-Shenzhen for technical support.

JHW and GZX conceived and designed the experiments. FYH, PX and YHQ collected the clinical samples. FJG, JKL and FC analyzed sequencing data. YHQ, YJZ, QC and FJG recruited patients, performed clinical examination of patients and clinical interpretation. FJG, GZX and FYH contributed data for the analysis, discussed and interpreted the results. JHW and FJG drafted and revised the manuscript. All authors read and approved the manuscript.

This work was supported by the National Natural Science Foundation of China (Grant NSFC81770944, 81770925, 81790641, the Non-profit Central Research Institute Fund of Chinese Academy of Medical Sciences 2018PT32019).

Please contact authors for data requests.

The study was in accordance with the Declaration of Helsinki and approved by the Ethics Committee of the Eye and ENT Hospital of Fudan University.

Written informed consent was obtained from all the subjects or their guardians.

The authors declare that they have no competing interests.
